---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-075932"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:37:08.425299+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics appoints John Cox as President and CEO, succeeding Joshua Brumm

## Summary
- John Cox appointed President and CEO effective March 25, 2024; also elected Class I director.
- Joshua Brumm resigns as CEO and from the Board; will serve as consultant for 12 months.
- Cox receives $700K base salary, up to 60% annual bonus, and option for 679,853 shares.
- Brumm gets separation: 12 months salary, COBRA, and partial equity acceleration.
- Board adopts 2024 Inducement Equity Plan authorizing 900,000 shares for new hires.

## SEC filing metadata
- accession: 0001193125-24-075932
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000119312524075932/0001193125-24-075932-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000119312524075932/d93072d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-075932
- JSON: https://secwatch.observer/filing/0001193125-24-075932.json
- Plain text: https://secwatch.observer/filing/0001193125-24-075932.txt

## Key facts
- Executive change
  Joshua Brumm departed as Chief Executive Officer at Dyne Therapeutics, Inc..
  - Action: succeeded
  - Role: Chief Executive Officer
  source text: succeeding Joshua Brumm
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000119312524075932/0001193125-24-075932-index.htm
- Executive change
  John Cox was elected as Class I Director at Dyne Therapeutics, Inc..
  - Action: elected
  - Role: Class I Director
  source text: Mr. Cox was elected as a Class I director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000119312524075932/0001193125-24-075932-index.htm
- Executive change
  John Cox was appointed as President and Chief Executive Officer at Dyne Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: had appointed John Cox as President and Chief Executive Officer of the Company succeeding Joshua Brumm
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000119312524075932/0001193125-24-075932-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.